



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2023 [Online ahead of print]

To cite this Article:

Dukić V, Muršić D, Popović Grle S, et al. **Monocyte related haematological indices in acute exacerbations of COPD – a new biomarker?** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2023.2706

 ©The Author(s), 2023
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Monocyte related haematological indices in acute exacerbations of COPD – a new biomarker?

Višnja Dukić,¹ Davorica Muršić,² Sanja Popović Grle,^{2,3} Marko Jakopović,^{2,3} Alen Ružić,⁴
Andrea Vukić Dugac^{2,3}

¹Thalassotherapia Crikvenica, Special Hospital for Medical Rehabilitation of the Primorsko-Goranska County, Crikvenica

²Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb

³School of Medicine, University of Zagreb

⁴Clinic for Cardiovascular Diseases, Clinical Hospital Centre Rijeka, Croatia

Corresponding author: Assistant Professor Vukić Dugac Andrea, MD, PhD, School of Medicine, University of Zagreb, Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10 000 Zagreb, Croatia. Tel. +385012385242 - Fax: +385012385251. E-mail: adugac71@gmail.com

Funding: The authors report no involvement in the research by the sponsor that could have influenced the outcome of this work.

Contribution: Author AVD and author AR have given substantial contributions to the design of the manuscript, author VD, DM, and author MJ to acquisition, analysis and interpretation of the data. All authors have participated to drafting the manuscript, authors AVD and MJ revised it critically. All authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Availability of data and materials: The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate: The Ethics Committee of University Hospital Centre Zagreb and University of Zagreb School of Medicine (Zagreb, Croatia) approved the study in January 2013. The committee assessed the planned project as ethically unobjectionable. Written consent to participate was obtained from all study participants.

Patient consent for publication: Not applicable.

Informed consent: Written informed consent was obtained from a legally authorized representatives for anonymized patient information to be published in this article. The manuscript does not contain any individual person's data in any form.

Abstract

C-reactive protein (CRP) and leukocyte count are standard tools for recognising inflammation in COPD patients. This study aimed to find if there is a pattern in monocyte related haematological indices - monocyte to neutrophil ratio (MNR) and monocyte to lymphocyte ratio (MLR) - which could be helpful in differentiating COPD patients in need for hospitalization due to acute exacerbation of COPD or differentiating frequent COPD exacerbators from non-frequent COPD exacerbators. The study included 119 patients with COPD and 35 control subjects, recruited at the Clinic for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Croatia. Complete blood count was performed on Sysmex XN-1000, CRP on Cobas c501, and Fbg on BCS XP analyser. Data were analysed with MedCalc statistical software. The COPD patients were divided into three groups – frequent exacerbators (FE), non-frequent exacerbators (NFE), patients hospitalized for acute COPD exacerbations (HAE) and the control group were healthy smokers (HS). A statistically significant difference was found in the values of MNR while comparing these groups of patients: FE vs HAE ($p < 0.000$), NFE vs HAE ($p < 0.000$) and HS vs HAE ($p < 0.001$); and for the values of MLR: FE vs HAE ($p < 0.022$), NFE vs HAE ($p < 0.000$) and HS vs HAE ($p < 0.000$). As MLR and MNR have shown the statistical difference comparing the group of HAE to NFE, FE and HS, MLR and MNR could be valuable and available markers of acute COPD exacerbations and need for hospitalization.

Key words: haematological indices; monocytes; COPD; biomarker.

Introduction

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent respiratory symptoms and airflow limitation. It is caused by significant exposure to harmful substances or gases, most frequently cigarette smoking [1]. COPD has become the third most common cause of death in the world [2] and has a big economic and social burden with a prevalence of 11.7% globally [3].

As COPD is not a unique disease, there has been a need for distinguishing certain COPD phenotypes, to achieve better management and disease prognosis. Miravittles *et al.* [4] proposed these four phenotypes of COPD: infrequent exacerbators with either chronic bronchitis or emphysema; overlap COPD-asthma, frequent exacerbators with emphysema predominant; and frequent exacerbators with chronic bronchitis predominant. The COPD exacerbator phenotype is characterised by two or more exacerbations per year [4]. Frequent exacerbations cause acceleration in lung function and health status decline (measured by SGRQ), as well as increased mortality [5] and number of comorbidities. It is reported that 13-47% of COPD patients are frequent exacerbators [6].

Acute exacerbation of COPD (AECOPD) is defined as a worsening of the patient's baseline dyspnoea, cough and/or sputum production which must be treated with antibiotics or oral steroids. AECOPD is independently associated with a higher risk of mortality in patients with COPD [7], i.e., mortality rates were 43% - 59% after 1 year [8,9]. Even a single COPD exacerbation leads to a significant increase in rates of decline in the lung function, i.e., pre- and postbronchodilator FEV1 and FVC [10]. Reducing the frequency of exacerbations is one of the main goals of COPD therapy and follow-up.

Plasma fibrinogen, CRP and leukocyte count are the most frequently used inflammatory biomarkers in COPD, and it is known that patients with increased levels of these biomarkers (all three) are more prone to developing exacerbations [11].

A lot of effort is put into searching for a perfect COPD biomarker but still the history of previous exacerbations is strongly associated with future exacerbations risk and no known biomarker provides additional information on exacerbation risk. In two large cohorts the combination of sRAGE and CRP best modelled total exacerbation frequency over the previous 12 months and biomarkers CC16 and SP-D were each individually predictive of mortality. The conclusion of the analyses by Zemans *et al.* is that multiple biomarkers are much more strongly predictive than individual biomarkers, so approval of a panel of multiple biomarkers should be considered as biomarkers for COPD [12].

It is still necessary to find a biomarker that would be widely available and affordable. That potential lies in haematological indices which are easily calculated from a standard complete blood count.

Haematological indices have been recognized through many studies as useful additional markers in many acute and chronic medical conditions. By now, the most studied is the neutrophil to lymphocyte ratio (NLR) which is associated with outcome prognosis in sepsis [13], solid tumours [14] and other inflammatory and chronic conditions. Platelet related indices

are a potential inflammatory marker in various inflammatory diseases, including COPD [15]. In this study special attention was given to monocyte related haematological indices which have shown a significant pattern in differentiating patients in acute exacerbation of COPD in need of hospitalization.

This study aimed to determine differences in monocyte-related haematological indices among four groups of patients – healthy smokers, non-frequent exacerbators, frequent exacerbators, and patients hospitalized for acute COPD exacerbation. Monocyte-related indices were compared to common inflammatory parameters (CRP, Fbg, WBC) as well, and so was the influence of most frequent COPD comorbidities. The goal of the analysis was to find whether there is an adequate biomarker in haematological indices that could help differentiate COPD phenotypes, exacerbation severity and indication for hospitalization. By the authors' best knowledge, the indices we have evaluated have not been studied in these groups of patients so far.

Materials and Methods

Subjects

The study was retrospective and included a total of 154 individuals - 119 COPD patients and 35 healthy smokers (HS) in the control group. The COPD patients were divided into three groups – 41 frequent exacerbators (FE), 41 non-frequent exacerbators (NFE) and 37 patients with known diagnosis of COPD hospitalized for acute COPD exacerbation (HAE). Frequent exacerbators are, as earlier explained, patients with two or more COPD exacerbations per year.

The Ethics Committee of University Hospital Centre Zagreb and University of Zagreb School of Medicine (Zagreb, Croatia) approved the study. The study was conducted at the University Hospital Centre Zagreb, Clinical Department for Lung Diseases Jordanovac, from May to October 2013. All patients provided written informed consent for participation. The study was conducted in accordance with the Declaration of Helsinki of the World Medical Association; and was registered at ClinicalTrials.gov before the enrolment of the first patient: NCT02092675 (<http://clinicaltrials.gov>).

The study was cross-sectional, the 154 subjects' data were collected according to chronological order of the ambulatory visits and hospitalizations due to the AECOPD at Clinical Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb. 35/154 were cigarette smokers with no diagnosis of COPD or other lung disease.

COPD was diagnosed by a specialist pulmonologist according to the GOLD criteria, and patients were screened for eligibility and recruited during ambulatory visits at the outpatient

clinic, or during hospitalization for the AECOPD. GOLD criteria for COPD diagnosis, alongside with signs and symptoms, is the forced expiratory volume in 1 second (FEV1) /forced vital capacity (FVC) value <0.70. Consecutive patients, male or female, age >40 years with objectively confirmed COPD were included. Patients had to be active smokers or ex-smokers with 10 or more pack-years history and have adequate COPD therapy with no changes within previous month.

Exclusion criteria were the change in COPD medications within the previous month, malignant diseases, acute cardiovascular event or clinically manifest cardiovascular disease, other non-regulated chronic diseases (arterial hypertension, diabetes mellitus), acute inflammatory conditions, women of reproductive age.

The control group consisted of healthy smokers with the same inclusion and exclusion criteria as for COPD patients, except they do not have a COPD diagnosis.

Methods and laboratory tests

For the analysis of complete blood count, platelet parameters, total leukocyte and lymphocyte count, we used blood samples collected in EDTA tubes. Blood for CRP measurement in serum was collected into the tubes without additive.

Leukocyte, lymphocyte and platelet counts, as a part of a complete blood count, were performed on the Sysmex XN-1000 analyser (Sysmex Corporation, Kobe, Japan). Leukocyte, lymphocyte and platelet counts are provided after the instrument has separated them according to the different signals, and MPV and PDW were calculated by the software. PCT was analysed by the electrochemiluminescence immunoassay (ECLIA) method on Cobas 6000 - module e601 (Roche Diagnostics, Mannheim, Germany). Immunoturbidimetry was a method used for the CRP determination on the Cobas c501 analyser (Roche Diagnostics GmbH, Mannheim, Germany). The measurement of Fbg was performed on BCS XP analyser (Siemens Healthcare Diagnostics, Marburg, Germany).

Statistical analysis

A Kolmogorov-Smirnov test was used for normal distribution testing. All data were non-parametric, so they were presented as median with interquartile range, while only age was presented as median with minimum and maximum. Differences between controls and COPD patients were tested by a Mann-Whitney Rank Sum test, while Kruskal-Wallis One Way

Analysis of Variance on Rank test was used in case of comparison between three or more groups of participants, and Pearson correlation was used for measuring relationships between variables. Data were considered statistically significant if $p < 0.05$. Statistical analysis was performed by SPSS for Windows version 21.0 (IBM Corp., Armonk, NY, USA).

Results

The baseline characteristics of study participants are shown in Table 1. The study included 119 COPD patients and 35 healthy smokers as controls. 35/154 (22.7%) were healthy cigarette smokers, and COPD patients were divided into three subgroups - 37 (24,0%) hospitalized for acute exacerbations, 41/154 (26,6%) non-frequent exacerbators and 41/154 (26,6%) frequent exacerbators.

Well-known inflammatory parameters – CRP, leukocyte count and fibrinogen showed increased levels in COPD patients compared to controls ($p < 0.0001$) and were statistically significantly different between the groups of our patients. As expected, HAE patients had significantly higher CRP and fibrinogen values than all other groups of patients.

The only statistically significant difference in leukocyte values was in NFE group compared to HAE group ($p = 0.024$). No statistically significant difference was found in HS *vs* NFE ($p > 0.999$), in HS *vs* FE ($p > 0.999$), HS *vs* HAE ($p = 0.150$) as well as NFE *vs* FE ($p > 0.999$). There was no statistically significant difference in FE *vs* HAE ($p = 0.168$).

When platelet to lymphocyte ratio (PLR) was compared, statistically significant difference was found comparing these groups of participants: HS *vs* HAE ($p < 0.000$), NFE *vs* HAE ($p < 0.000$) and FE *vs* HAE ($p < 0.000$), while no statistically significant difference was found comparing the other groups: HS *vs* NFE ($p < 0.116$), HS *vs* FE ($p < 0.105$), NFE *vs* FE ($p < 1.000$).

No statistically significant difference was found in the values of haematological index platelet to mean particular volume (platelet/MPV) while comparing the following groups of our participants: NFE *vs* HS ($p < 1.000$), NFE *vs* FE ($p < 1.000$), HS *vs* FE ($p < 1.000$), and FE *vs* HAE ($p < 0.214$), Statistically significant difference was found in platelet/MPV between these groups of participants: NFE *vs* HAE ($p = 0.008$), and HS *vs* HAE ($p < 0.034$).

Regarding the neutrophil to lymphocyte ratio (NLR) the results were as follows: HS *vs* HAE ($p < 0.000$), NFE *vs* HAE ($p < 0.000$) and FE *vs* HAE ($p < 0.000$) while no statistically significant difference was shown between HS *vs* NFE ($p < 0.371$), HS *vs* FE ($p < 0.259$), and NFE *vs* FE ($p < 1.000$).

The focus of our work are the following values: we have found a statistically significant difference in the values of a haematological index MNR (monocyte to neutrophil ratio) while

comparing these groups of our participants: FE vs HAE ($p < 0.000$), NFE vs HAE ($p < 0.000$) and HS vs HAE ($p < 0.001$) (Figure 1).

A statistically significant difference was found in the values of haematological index MLR (monocyte to lymphocyte ratio) while comparing the same groups of participants: FE vs HAE ($p < 0.022$), NFE vs HAE ($p < 0.000$) and HS vs HAE ($p < 0.000$) (Figure 2).

There was no statistically significant difference between FE and NFE ($p = 1.000$) regarding MNR and MLR.

Concerning comorbidities, no significant difference in MLR nor MNR values distribution was found between the groups of patients with different comorbidities ($p = 0.05$). Groups according to comorbidities were as follows: no comorbidities, arterial hypertension, diabetes mellitus, cardiovascular disease. No statistically significant difference was found neither when the comorbidities were clustered as arterial hypertension + diabetes mellitus, arterial hypertension + cardiovascular diseases, nor arterial hypertension + cardiovascular diseases + diabetes mellitus.

Statistically significant correlations between CRP, fibrinogen and MLR values are found in all participants of this study - in healthy controls as well as in every COPD patient's group – HAE, NFE and FE. There was no statistically significant correlation between the MNR and CRP, nor between the MNR and fibrinogen.

There was no statistically significant difference in MNR and MLR distribution amongst the groups of different comorbidities (CVD, AH, DM, no comorbidities group).

Discussion

Study demonstrated that monocyte to neutrophil and monocyte to lymphocyte ratio have a significant pattern across the subgroups of our patients and the healthy smokers as a control group. This pattern could have a role in differentiating patients in acute COPD exacerbation in need for hospitalization, i.e., to distinguish COPD exacerbation from other differential diagnoses in the emergency department. By the author's best knowledge, monocyte to neutrophil and monocyte to lymphocyte ratio have not been in the focus of research by now in patient groups like the ones in this work.

By now, the most studied was the neutrophil to lymphocyte ratio (NLR). The studies have shown that the NLR is a predictor of both AECOPD and mortality, could be used in defining COPD exacerbation endotypes and has been used in other diseases except COPD [16,17].

Lymphocyte to monocyte ratio was studied and found to be a potentially useful marker in patients with urological and colorectal cancers as a prognostic marker, in mood disorders as an inflammatory marker [18-20]. Lymphocyte to monocyte ratio was found to be more sensitive than platelet to lymphocyte ratio in differentiating glioblastoma (due to the systemic inflammation component) from brain metastasis. Elevated MLR and NLR may be unfavourable prognostic factors for clinical outcomes in patients with hyperglycaemia during pregnancy.

Neutrophil to monocyte as well as neutrophil to lymphocyte ratio were found as potentially useful in predicting lupus nephritis [21]. In one study the NMLR (neutrophil count/(monocyte count + lymphocyte count)) is shown to be more powerful than the NLR in discriminating tuberculosis from non-TB infectious lung diseases [22]. In a study by Rahimirad *et al.* LMR did not show significant relation to in-hospital death in AECOPD, while NLR ratio was associated with in-hospital mortality [23]. In a South Korean study by Lee *et al.* [24] there has been evaluated a reference value for LMR, NLR, PLR and MPV among 12160 samples from patients without any medical history. The mean LMR value was 5.31, but it is still necessary to adjust normal values based on race, age and sex in further studies.

A statistically significant correlation of CRP and MLR values was proven in a study on knee osteoarthritis [25], and the correlation was shown in our study as well, while neither CRP nor fibrinogen show statistically significant correlation with MNR values in our study or in the earlier published studies.

The results of our study demonstrated a significant MLR and MNR pattern in HAE patients compared to other two groups of COPD patients (FE, NFE) and the control group of HS. This could mean that MLR and MNR could be a good biomarker of AECOPD and the need for hospitalization due to AECOPD. These findings may help in differentiating acute COPD exacerbation from other causes of acute dyspnea in COPD patients, such as pulmonary thromboembolism, pneumonia, or congestive heart failure, when considered together with CRP, fibrinogen and relevant clinical parameters.

We did not find a statistically significant pattern in none of the haematological indices analysed to differentiate NFE from FE, which was one of the motivating ideas for this work.

The results we obtained are compared to the known inflammatory biomarkers, across the groups of participants and across the groups of patients with different comorbidities, independent of COPD exacerbations.

As CRP and fibrinogen are well known for their role as biomarkers in inflammatory conditions, our results are in concordance with known data – CRP and fibrinogen levels are higher in HAE group compared to other groups of patients, and CRP level is higher in FE compared to NFE

and other groups of participants, though fibrinogen and leukocyte count had no significant difference in FE vs NFE groups. As Perera *et al.* concluded frequent exacerbators have persistently higher systemic inflammatory markers [26].

Concerning PLR we have confirmed what was already proven in earlier research - PLR values are higher in the acute exacerbations of COPD compared to stable disease and healthy controls, and PLR values were even higher in life threatening acute respiratory failure [27,28]. PLR could also be considered as a novel COPD exacerbation biomarker.

The major limitation of our study was the limited sample size; consequently, there are a relatively small number of subjects in each group. Study is a single-centre one; and only spot parameters were analysed with no follow-up values. Due to this limitation, it was not possible to set a cut-off value for MLR and MNR which could be used in clinical routine for the decision of hospitalization. Healthy smokers as a control group were on average younger than COPD patients (57.8 and 69.6 years, respectively), had a lower BMI and less comorbidities. There were more male than female participants (101 vs 53, respectively). Patients hospitalized for acute exacerbation of COPD were older than healthy smokers, non-frequent and frequent exacerbators (73, 57.8, 68 and 67.9 years, respectively).

Conclusions

In conclusion, the results of our study have demonstrated a statistically significant difference in monocyte to neutrophil and monocyte to lymphocyte ratio between hospitalized patients with acute exacerbation of COPD and patients with stable COPD (FE and NFE). This could mean that MLR and MNR could be valuable and available biomarkers for the prediction of acute exacerbations of COPD and need for hospitalization. To our knowledge, this is the first study to identify the MLR and MNR as a novel and reliable potential predictor for AECOPD. Further prospective studies are needed.

References

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
2. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1151-10.
3. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. *J Glob Health* 2015;5:020415.

4. Miravittles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). *Prim Care Respir J* 2013;22:117-21.
5. Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. *Int J Chron Obstruct Pulmon Dis* 2012;7:653-61.
6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010;363:1128-38.
7. Soler-Cataluña JJ, Martínez-García MA, Sánchez PR, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005;60:925-31.
8. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. *Am J Respir Crit Care Med* 1996;154:959-67.
9. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. *JAMA* 1995;274:1852-7.
10. Halpin DMG, Decramer M, Celli B, et al. Effect of a single exacerbation on decline in lung function in COPD. *Res Med* 2017;128:85-91.
11. Thomsen M, Truls SI, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. *JAMA* 2013;309:2353-61.
12. Zemans RL, Jacobson S, Keene J, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. *Respir Res* 2017;18:117.
13. Huang Z, Fu Z, Huang W, et al. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. *Am J Emerg Med* 2020;38:641-7.
14. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014;106:dju124.
15. Hlapčić I, Somborac-Baćura A, Popović-Grle S, et al. Platelet indices in stable chronic obstructive pulmonary disease – association with inflammatory markers, comorbidities and therapy. *Biochem Med (Zagreb)* 2020;30:010701.
16. Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. *Eur Res Review* 2018;27:170113.
17. Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. *Int J Chron Obstruct Pulmon Dis* 2018;13:2721-30.
18. Tan D, Fu Y, Tong W, et al. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. *Int J Surg* 2018;55:128-38.
19. Mazza MG, Tringali AGM, Rosetti A, et al. Cross-sectional study of neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in mood disorders. *Gen Hosp Psychiatry* 2019;58:7-12.
20. Baran O, Kemerdere R, Korkmaz TS, et al. Can preoperative neutrophil to lymphocyte, lymphocyte to monocyte, or platelet to lymphocyte ratios differentiate glioblastoma from brain metastasis? *Medicine (Baltimore)* 2019;98:e18306.

21. Liu P, Li P, Peng Z, et al. Predictive value of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-neutrophil ratio, and neutrophil-to-monocyte ratio in lupus nephritis. *Lupus* 2020;29:1031-9.
22. Jeon YL, Lee WI, Kang SY, et al. Neutrophil-to-monocyte-plus-lymphocyte ratio as a potential marker for discriminating pulmonary tuberculosis from nontuberculosis infectious lung diseases. *Lab Med* 2019;50:286-91.
23. Rahimirad S, Ghaffary MR, Rahimirad MH, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease. *Tuberk Toraks* 2017;65:25-31.
24. Lee JS, Kim NY, Na SH, et al. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. *Medicine (Baltimore)* 2018;97:e11138.
25. Gao K, Zhu W, Liu W, et al. Diagnostic value of the blood monocyte–lymphocyte ratio in knee osteoarthritis. *J Int Med Res* 2019;47:4413-21.
26. Perera WR, Hurst JR, Wilkinson TMA, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. *Eur Respir J* 2007;29:527-34.
27. El-Gazzar AG, Kamel MH, Elbahnasy OKM, et al. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. *Expert Rev Respir Med* 2020;14:111-6.
28. Karadeniz G, Aktoğu S, Erer F, et al. Predictive value of platelet-to-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. *Biomark Med* 2016;10:701-10.

Table 1. Baseline characteristics, inflammatory and monocyte-related parameters of controls and patients with COPD.

Parameter	Controls (HS) n=35	NFE n=41	FE n=41	HAE n=37
Age (years)	58 (45-74)	68 (49-88)	68 (48-88)	73 (61-90)
Sex				
Males; N/total	19/35	28/41	31/41	23/37
Females; N/total	16/35	13/41	10/41	14/37
Smoking status				
Smoker	35/35	17/41	15/41	12/37
Ex-smoker	0/35	24/41	26/41	24/37
CRP (mg/L)	1.7 (0.8-3.4)	2.7 (1.6-4.1)	5.6 (2.5-14.8)	24 (10.2-95.5)
Fbg (g/L)	3.7 (3.2-4.7)	4.1 (3.7-4.9)	4.8 (3.8-6.1)	5.1 (4.2-7.7)
WBC ($\times 10^9/L$)	7.9 (6.7-9.2)	7.8 (6.6-8.8)	8.0 (6.9-9.6)	9.5 (7.2-14.0)
Lymphocytes ($\times 10^9/L$)	2.2 (1.9-2.7)	1.9 (1.5-2.2)	1.9 (1.45-2.2)	0.9 (0.58-1.2)
Monocytes ($\times 10^9/L$)	0.6 (0.5-0.7)	0.6 (0.5-0.7)	0.7 (0.6-0.8)	0.5 (0.375-0.8)
MNR	0.116 (0.093-0.135)	0.116 (0.098-0.157)	0.128 (0.101-0.165)	0.071 (0.034-0.099)
MLR	0.25 (0.222-0.313)	0.333 (0.255-0.414)	0.353 (0.310-0.512)	0.556 (0.382-1.042)

Smoking status is presented as absolute numbers and all other data are presented as the median (interquartile range), except for age that is presented as median (minimum-maximum). Data were analysed by Mann-Whitney Test. COPD - chronic obstructive pulmonary disease. HS – healthy smokers. NFE – non-frequent exacerbators. FE – frequent exacerbators. HAE – hospitalized for acute exacerbation of COPD. CRP – C-reactive protein. WBC – white blood cells. MNR – monocyte to neutrophil ratio. MLR – monocyte to lymphocyte ratio.

Figure 1. MNR values are statistically significantly different in the group of HAE patients compared to the groups of FE, NFE and HS ($p < 0.05$). MNR – monocyte to lymphocyte ratio, HAE – patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease, FE – frequent exacerbators of chronic obstructive pulmonary disease, NFE – non-frequent exacerbators of chronic obstructive pulmonary disease.




Figure 2. MLR values are statistically significantly different in the group of HAE patients compared to the groups of FE, NFE and HS ($p < 0.05$). MNR – monocyte to lymphocyte ratio, HAE – patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease, FE – frequent exacerbators of chronic obstructive pulmonary disease, NFE – non-frequent exacerbators of chronic obstructive pulmonary disease.

